CanSino Biologics Inc. is a biopharmaceutical company incorporated in 2009, dedicated to providing high-quality, innovative, and affordable vaccines aimed at enhancing global public health security. The company has developed five integrated platform technologies and a diverse pipeline of products designed to prevent over 10 diseases. Notable products include the Ad5-EBOV Ebola vaccine, Meningococcal Conjugate Vaccines such as Menhycia® and Menphecia®, as well as the inhaled COVID-19 vaccine Convidecia Air®.

Services include:
– Anatomical Therapeutic Chemical (ATC) Classification
– Biologics
– Vaccine Development
– Clinical Trial Management
– Regulatory Affairs
– Quality Control and Assurance

CanSino Biologics Inc. continues to be a pivotal supplier to the pharmaceutical industry, contributing significantly to vaccine innovation and public health efforts. For more information, please visit cansinotech.com.